Trials / Completed
CompletedNCT02058589
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant
Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults 18 Years of Age or Older With Renal Transplant
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 265 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine administered on a 0- and 1- to 2-months schedule in adults 18 years of age or older who are receiving chronic immunosuppressive therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Herpes Zoster vaccine GSK1437173A | 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm. |
| DRUG | Placebo | 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm. |
Timeline
- Start date
- 2014-03-20
- Primary completion
- 2016-05-11
- Completion
- 2017-04-13
- First posted
- 2014-02-10
- Last updated
- 2018-08-01
- Results posted
- 2018-08-01
Locations
34 sites across 9 countries: Belgium, Canada, Czechia, Finland, Italy, Panama, South Korea, Spain, Taiwan
Source: ClinicalTrials.gov record NCT02058589. Inclusion in this directory is not an endorsement.